{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:53:44Z","timestamp":1791179624215,"version":"4.1.0"},"reference-count":33,"publisher":"The Journal of Rheumatology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The Plasma Exchange and Glucocorticoids in Severe Antineutrophil Cytoplasmic Antibody\u2013Associated Vasculitis (PEXIVAS) trial evaluated plasma exchange (PLEX) and glucocorticoid dose in antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV). This study reanalyzed the PEXIVAS trial using Bayesian methods to focus on patients with diffuse alveolar hemorrhage (DAH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the PEXIVAS trial, adults with AAV and kidney injury and\/or DAH were randomized to receive PLEX or no PLEX and reduced- or standard-dose glucocorticoids. This study evaluated 1-year survival and severe infection among participants with DAH, no DAH, and severe DAH (oxygen saturation \u2264 85% on room air or mechanical ventilation) across multiple priors. The secondary outcome was severe infection (leading to hospitalization, intravenous antibiotics, or death). This study calculated mean hazard ratios (HRs) for survival and odds ratios (ORs) for infection, 95% credible intervals (CrIs), and probabilities of survival benefit (HR &lt; 1) and infection (OR &gt; 1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 704 participants (191 with DAH and 61 with severe DAH), using noninformative priors, the probability of improved survival was 93% for participants with DAH receiving PLEX (HR 0.52; 95% CrI 0.21-1.26) and 67% for those without DAH (HR 0.86; 95% CrI 0.43-1.71). Participants receiving reduced-dose glucocorticoids had a 98% probability of improved survival without DAH (HR 0.46; 95% CrI 0.22-0.95) but a 12% probability with severe DAH (HR 2.02; 95% CrI 0.64-6.35). Plasma exchange increased the odds of severe infection (OR 1.25; 95% CrI 0.92-1.70; 92% probability of OR &gt; 1), whereas reduced-dose glucocorticoids decreased the odds of infection (OR 0.85; 95% CrI 0.63-1.15; 85% probability of OR &lt; 1). Results were consistent across priors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with AAV and DAH may benefit from PLEX. Reduced-dose glucocorticoids improve survival for individuals without DAH but may be harmful in patients with severe DAH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0796","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:20:22Z","timestamp":1776255622000},"page":"1117-1124","source":"Crossref","is-referenced-by-count":2,"title":["Management of Antineutrophil Cytoplasmic Antibody\u2013Associated Alveolar Hemorrhage: A Bayesian Reanalysis of the PEXIVAS Trial"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6024-9030","authenticated-orcid":false,"given":"Omri A.","family":"Arbiv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-7323","authenticated-orcid":false,"given":"Lee","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-2976","authenticated-orcid":false,"given":"Sindhu R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0246-594X","authenticated-orcid":false,"given":"Andrea S.","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1276","authenticated-orcid":false,"given":"Kuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026100422250784000_53.10.1117.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537"},{"key":"2026100422250784000_53.10.1117.2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1164\/rccm.202308-1426OC","article-title":"Alveolar hemorrhage in antineutrophil cytoplasmic antibody-associated vasculitis: results of an international randomized controlled trial (PEXIVAS)","volume":"209","author":"Fussner","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100422250784000_53.10.1117.3","doi-asserted-by":"publisher","DOI":"10.2307\/2983527"},{"key":"2026100422250784000_53.10.1117.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003563"},{"key":"2026100422250784000_53.10.1117.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.07.006"},{"key":"2026100422250784000_53.10.1117.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01295-9"},{"key":"2026100422250784000_53.10.1117.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.012"},{"key":"2026100422250784000_53.10.1117.8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.201910-2019ED","article-title":"Bayesian analysis in critical care medicine","volume":"201","author":"Yarnell","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100422250784000_53.10.1117.9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2213-2600(20)30471-9","article-title":"Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?","volume":"9","author":"Yarnell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026100422250784000_53.10.1117.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201905-0968OC"},{"key":"2026100422250784000_53.10.1117.11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.rdc.2018.01.003","article-title":"Applied Bayesian methods in the rheumatic diseases","volume":"44","author":"Johnson","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"2026100422250784000_53.10.1117.12","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1093\/rheumatology\/keaa803","article-title":"Effectiveness of initial methotrexate-based treatment approaches in early rheumatoid arthritis: an elicitation of rheumatologists\u2019 beliefs","volume":"60","author":"Pokharel","year":"2021","journal-title":"Rheumatology"},{"key":"2026100422250784000_53.10.1117.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110765"},{"key":"2026100422250784000_53.10.1117.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100632"},{"key":"2026100422250784000_53.10.1117.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100665"},{"key":"2026100422250784000_53.10.1117.16","first-page":"1125","article-title":"Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials","volume":"34","author":"Huber","year":"2007","journal-title":"J Rheumatol"},{"key":"2026100422250784000_53.10.1117.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110013"},{"key":"2026100422250784000_53.10.1117.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.071169"},{"key":"2026100422250784000_53.10.1117.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.14276"},{"key":"2026100422250784000_53.10.1117.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.08.010"},{"key":"2026100422250784000_53.10.1117.21","doi-asserted-by":"crossref","unstructured":"Spiegelhalter DJ , Abrams KR , Myles JP. Prior distributions. In: Bayesian Approaches to Clinical Trials and Health-Care Evaluation. John Wiley & Sons; 2004:139-80.","DOI":"10.1002\/0470092602.ch5"},{"key":"2026100422250784000_53.10.1117.22","doi-asserted-by":"crossref","first-page":"e0196009","DOI":"10.1371\/journal.pone.0196009","article-title":"Effect of plasma exchange on in-hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: a propensity-matched analysis using a nationwide administrative database","volume":"13","author":"Uechi","year":"2018","journal-title":"PLOS One"},{"key":"2026100422250784000_53.10.1117.23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026100422250784000_53.10.1117.24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard-2024-226339","article-title":"Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"84","author":"Nagle","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026100422250784000_53.10.1117.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0145-y"},{"key":"2026100422250784000_53.10.1117.26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.12.2077"},{"key":"2026100422250784000_53.10.1117.27","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026100422250784000_53.10.1117.28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007010090"},{"key":"2026100422250784000_53.10.1117.29","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.131"},{"key":"2026100422250784000_53.10.1117.30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11926-022-01064-8","article-title":"Is there still a role of plasma exchange in the current management of ANCA-associated vasculitides?","volume":"24","author":"Toyoda","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"2026100422250784000_53.10.1117.31","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/1744-9987.14173","article-title":"Complications of therapeutic plasma exchange: a retrospective, single-center study of 2505 procedures performed in 338 patients over 15 years","volume":"28","author":"Vural","year":"2024","journal-title":"Ther Apher Dial"},{"key":"2026100422250784000_53.10.1117.32","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20143"},{"key":"2026100422250784000_53.10.1117.33","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-020-00002-1"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:25:26Z","timestamp":1791177926000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.3899\/jrheum.2025-0796"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0796","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}